Why do patients with inflammatory arthritis often score states "worse than death" on the EQ-5D? An investigation of the EQ-5D classification system

Value in Health

Volumn 12, Issue 6, 2009, Pages 1026-1034

  Harrison, Mark J ^a   Davies, Linda M ^a   Bansback, Nick J ^b   McCoy, Melanie J ^a,c   Farragher, Tracey M ^a   Verstappen, Suzanne M M ^a   Hassell, Andrew ^d   Symmons, Deborah P M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ST PAUL S HOSPITAL   (Canada)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

Arthritis; EQ 5D; Health related quality of life; Health state utility; Quality adjusted life years

Indexed keywords

METHYLPREDNISOLONE; PLACEBO; STEROID;

ADULT; ANXIETY; ARTHRITIS; ARTICLE; DEPRESSION; DISABILITY; DISEASE SEVERITY; EUROPE; EUROQOL 5D; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOMES RESEARCH; PAIN ASSESSMENT; PATIENT MOBILITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SELF CARE; SHORT FORM 36; STEROID THERAPY; UNITED KINGDOM; VISUAL ANALOG SCALE;

AGED; ARTHRITIS; ARTHRITIS, RHEUMATOID; DEATH; DEPRESSION; FEMALE; GREAT BRITAIN; HEALTH STATUS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PAIN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE;

EID: 67651227362     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00565.x     Document Type: Article

References (46)

1. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes (3rd ed.). Oxford : Oxford University Press, 2005.
2. National Institute for Health and Clinical Excellence. A Guide to NICE. London : National Institute for Clinical Excellence, 2005.
3. Ontario Ministry of Health and Long-Term Care. Ontario guidelines for economic analysis of pharmaceutical products. Internet 2004 August. Available from: http://www.health.gov.on.ca/english/providers/pub/drugs/economic/economic- mn.html [Accessed January 31, 2007 SD, Lyles A, Luce B, Grigar J. AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in U.S. health plans and pharmacy benefits management organizations. J Manag Care Pharm 2001 7 (4 272 82.
4. Macran S, Kind P. "Death" and the valuation of health-related quality of life. Med Care 2001 39 (3 217 27.
5. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990 16 (3 199 208.
6. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes 2003 1 : 54.
7. Patrick DL, Starks HE, Cain KC, et al. Measuring preferences for health states worse than death. Med Decis Making 1994 14 (1 9 18.
8. Lockhart LK, Ditto PH, Danks JH, et al. The stability of older adults' judgments of fates better and worse than death. Death Stud 2001 25 (4 299 317.
9. MVH Group. The Measurement and Valuation of Health: Final Report on the Modelling of Valuation Tariffs. York, UK : Centre for Health Economics, University of York, 1995.
10. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997 35 (11 1095 108.
11. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005 43 (3 203 20.
12. Wittrup-Jensen KU, Lauridsen J, Pedersen KM. Modelling Danish EuroQol (EQ-5D) tariffs by applying the time trade-off method. Health Economics Papers Series 2008. Odense, Denmark : The University of Southern Denmark.
13. Badia X, Roset M, Herdman M, Kind P. A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med Decis Making 2001 21 (1 7 16.
14. Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ 2002 11 (4 341 53.
15. Dolan P, Gudex C, Kind P, Williams A. A Social Tariff for EuroQol: Results from a UK General Population Survey. York : Centre for Health Economics, University of York, 1995.
16. Kopec JA, Willison KD. A comparative review of four preference-weighted measures of health-related quality of life. J Clin Epidemiol 2003 56 : 317 25.
17. Janssen MF, Birnie E, Haagsma JA, Bonsel GJ. Comparing the standard EQ-5D three-level system with a five-level version. Value Health 2008 11 (2 275 84.
18. Harrison MJ, Davies LM, Bansback NJ, et al. The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol 2008 35 (4 592 602.
19. Fransen M, Edmonds J. Reliability and validity of the EuroQol in patients with osteoarthritis of the knee. Rheumatology 1999 38 : 807 13.
20. Dolan P, Roberts J. Modelling valuations for Eq-5d health states: an alternative model using differences in valuations. Med Care 2002 40 (5 442 6.
21. Marra CA, Woolcott JC, Kopec JA, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ5D) and disease specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005 60 (7 1571 82.
22. Luo N, Chew LH, Fong KY, et al. A comparison of the EuroQol-5D and the Health Utilities Index mark 3 in patients with rheumatic disease. J Rheumatol 2003 30 (10 2268 74.
23. Russell AS, Conner-Spady B, Mintz A, et al. The responsiveness of generic health status measures as assessed in patients with rheumatoid arthritis receiving infliximab. J Rheumatol 2003 30 (5 941 7.
24. Conner-Spady B, Suarez-Almazor ME. Variation in the estimation of quality-adjusted life-years by different preference-based instruments. Med Care 2003 41 (7 791 801.
25. Marra CA, Rashidi AA, Guh D, et al. Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? Qual Life Res 2005 14 : 1333 44.
26. Franic DM, Pathak DS. Effect of including (versus excluding) fates worse than death on utility measurement. Int J Technol Assess Health Care 2003 19 (2 347 61.
27. Wolfe F, Hawley DJ. Measurement of the quality of life in rheumatic disorders using the EuroQol. Br J Rheumatol 1997 36 (7 786 93.
28. Pickard AS, De Leon MC, Kohlmann T, et al. Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care 2007 45 (3 259 63.
29. Hurst NP, Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997 36 (5 551 9.
30. Verstappen SMM, McCoy MJ, Roberts C, et al. A 3 week course of IM steroid injections may prevent the progression of very early inflammatory polyarthritis: results of the STIVEA trial. Ann Rheum Dis 2008 67 (Suppl. II S61.
31. Symmons DPM, Tricker K, Roberts C, et al. The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis. Health Technol Assess 2005 9 : 34.
32. Symmons D, Tricker K, Harrison M, et al. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs - results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial. Rheumatology 2006 45 : 558 65.
33. Davies LM, Fargher EA, Tricker K, et al. Is shared care with annual hospital review better value for money than predominantly hospital-based care in patients with established stable rheumatoid arthritis? Ann Rheum Dis 2007 66 (5 658 63.
34. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988 31 (3 315 24.
35. OMERACT. OMERACT, conference on outcome measures in rheumatoid arthritis clinical trials. Proceedings. Maastricht, The Netherlands, April 29-May 3, 1992. J Rheumatol 1993 20 (3 527 91.
36. Kirwan JR, Reeback JS. Stanford health assessment questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986 25 (2 206 9.
37. Prevoo MLL, Vanthof MA, Kuper HH, et al. Modified disease-activity scores that include 28-joint counts - development and validation in a prospective longitudinal-study of patients with rheumatoid-arthritis. Arthritis Rheum 1995 38 (1 44 8.
38. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992 30 (6 473 83.
39. Collett D. Modelling Survival Data in Medical Research (1st ed.). Boca Raton, FL : Chapman & Hall/CRC, 1994.
40. Stata statistical software computer program Version 9.2. College Station, TX : Stata Corporation, 2006.
41. Marra CA, Esdaile JM, Guh D, et al. A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care 2004 42 (11 1125 31.
42. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993 20 (3 557 60.
43. Krabbe PFM, Stalmeier PFM, Lamers LM, van Busschback JJ. An experimental study on three principal biases of the visual analogue scale. In Proceedings of the 21st Plenary Meeting of the EuroQol Group, Chicago, IL, September 16-18, 2004. Rotterdam, The Netherlands : EuroQol Group, 2004.
44. Elwood M. Critical Appraisal of Epidemiological Studies and Clinical Trials (2nd ed.). Oxford : Oxford University Press, 1998.
45. Patel S, Farragher T, Berry J, et al. Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum 2007 56 (7 2143 9.
46. Brennan A, Bansback N, Nixon R, et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology 2007 46 (8 1345 54.